Clinical Trial Update: A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Prospective clinical study evaluating bridging alloHSCT after obinutuzumab with chidamide and venetoclax in relapsed/refractory Philadelphia-negative ALL and B-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Chidamide (chidamide)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN